Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Whitehawk Therapeutics 5-Day RSI Related Terms
STU:3350 vs MDWD, IMUX, IVVD: 5-Day RSI Comparison
For the Biotechnology subindustry, Whitehawk Therapeutics's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Whitehawk Therapeutics 5-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Whitehawk Therapeutics's 5-Day RSI distribution charts can be found below:
* The bar in red indicates where Whitehawk Therapeutics's 5-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Whitehawk Therapeutics (STU:3350) has a 5-Day RSI of 51.94 as of Aug. 03, 2026. According to the industry distribution chart, Whitehawk Therapeutics ranks #1173 out of 1418 companies in the Biotechnology industry, placing it in the top 82.7%.
Is Whitehawk Therapeutics' 5-Day RSI too high?
Whitehawk Therapeutics' current 5-Day RSI is 51.94. The Biotechnology industry median 5-Day RSI is 42.17. Whitehawk Therapeutics' value of 51.94 is 23.2% above this industry median. Based on the distribution chart, Whitehawk Therapeutics ranks #1173 out of 1418 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Whitehawk Therapeutics has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Whitehawk Therapeutics' 5-Day RSI compare to MDWD and IMUX?
According to the Biotechnology industry distribution chart, Whitehawk Therapeutics ranks #1173 out of 1418 companies for 5-Day RSI. This places Whitehawk Therapeutics in the lower half of its industry. The industry median 5-Day RSI is 42.17. Whitehawk Therapeutics' value of 51.94 is 23.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Day RSI for a Biotechnology company?
The median 5-Day RSI among Biotechnology companies is 42.17, based on 1,418 companies in the industry. Companies in the top quartile (top 25%) have a 5-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 5-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Whitehawk Therapeutics's current 5-Day RSI of 51.94 is 23.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Day RSI mean?
A high 5-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 5-Day RSI is 42.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Whitehawk Therapeutics's current 5-Day RSI is 51.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Whitehawk Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Whitehawk Therapeutics (STU:3350) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.24, compared to a current price of €3.32 — trading 1283.3% above its estimated fair value. The current 5-Day RSI is 51.94 and 23.2% above the Biotechnology industry median of 42.17. Whitehawk Therapeutics' overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Day RSI calculated?
5-Day RSI is calculated from a company's financial statements. For Whitehawk Therapeutics (STU:3350), the current 5-Day RSI is 51.94 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Whitehawk Therapeutics (STU:3350) Overvalued in 2026?
Based on GuruFocus' analysis, Whitehawk Therapeutics stock appears to be overvalued.
The current stock price of €3.32 is trading 1283.3% above its estimated GF Value™ of €0.24.
GuruFocus considers Whitehawk Therapeutics to be Significantly Overvalued.
Key valuation signals for STU:3350:
5-Day RSI: 51.94
GF Value™: €0.24 vs. price of €3.32 (1283.3% above fair value)
Industry Position: 23.2% above the Biotechnology median (#1173 of 1418)
No single metric tells the full story. See the STU:3350 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
39GF Score
Get the complete analysis for STU:3350
5-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:3350 has been successfully added to your 
